#FDA approval

Azacitidine (Vidaza) was approved for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).

An Army veteran, retired firefighter and farmer, Jeff Meckstroth, 65, lives in Ohio. He has Stage IV metastatic non-small-cell lung cancer.

Extra vaccine doses, monoclonal antibodies and antivirals can help prevent severe illness.

“It is a really important development for our patients."

The personalized CAR-T therapy prolonged cancer remission compared with standard therapy.

Immunocompromised people ages 12 and older are also eligible for an additional shot.

Neoadjuvant Opdivo plus chemotherapy improved outcomes for people with operable non-small-cell lung cancer.

98% of people who received the customized immunotherapy responded to the one-time treatment.

Kimmtrak, the first approved T-cell receptor therapy, improved overall survival in a clinical trial.

The PreHevbrio vaccine produces higher antibody levels and offers faster protection.

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

The latest new cancer drugs approved by the Food and Drug Administration

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

Robert Califf headed the Food and Drug Administration for 10 months under Obama. Will he manage to implement his ideas this time around?

Scemblix was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia.